Very Positive Press Coverage Extremely Likely to Impact Amyris (AMRS) Share Price

Media stories about Amyris (NASDAQ:AMRS) have trended very positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amyris earned a news sentiment score of 0.56 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 100 out of 100, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

A number of equities research analysts recently issued reports on AMRS shares. Zacks Investment Research upgraded shares of Amyris from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Amyris in a report on Tuesday, May 23rd. Finally, ValuEngine cut shares of Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $31.13.

Amyris (NASDAQ:AMRS) traded down 10.41% during midday trading on Friday, hitting $2.41. 1,090,734 shares of the company traded hands. The company’s market capitalization is $47.73 million. The stock’s 50-day moving average price is $3.51 and its 200 day moving average price is $5.88. Amyris has a 12-month low of $2.40 and a 12-month high of $18.15.

Amyris (NASDAQ:AMRS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by $0.35. The firm had revenue of $25.68 million for the quarter, compared to the consensus estimate of $23.68 million. During the same period in the prior year, the company posted ($0.06) EPS. Amyris’s revenue was up 167.5% compared to the same quarter last year. On average, equities analysts forecast that Amyris will post ($3.98) EPS for the current year.

In related news, Director Patrick Y. Yang acquired 300,000 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was acquired at an average price of $0.29 per share, for a total transaction of $87,000.00. Following the completion of the acquisition, the director now owns 153,000 shares of the company’s stock, valued at approximately $44,370. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Very Positive Press Coverage Extremely Likely to Impact Amyris (AMRS) Share Price” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

What are top analysts saying about Amyris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit